Bristol Launches Zeposia For MS, Sees Advantages In The COVID-19 Environment
Executive Summary
After delaying the launch of the MS treatment due to the pandemic, Bristol now says the market is ready for a new launch. Immunology US business unit head Tina Deignan talked to Scrip about it.
You may also be interested in...
BMS Speeds Expansion Into Neuroscience With $14bn Karuna Buy
Bristol Myers Squibb will double its neuroscience portfolio from one to two drugs after it pays $330 per share for Karuna and its lead asset KarXT, accelerating the big pharma’s diversification plans.
MS Market Snapshot: New Options Confront Commercial Reality Of A Crowded Space
The multiple sclerosis drug market is more competitive than ever, though new options work through existing mechanisms of action. Unmet need remains despite numerous drugs, and competition clustered in the same classes creates pressure.
Zeposia’s Ulcerative Colitis Approval Provides BMS’s Beachhead Into GI
The second US approval for the S1P receptor agonist brings Bristol into the gastrointestinal space, and is just the starting point for the pharma in that arena, the company told Scrip.